Neurofibromatosis Type-1 Market – Significant Prevalence of Neurofibromatosis Type 1 and R&D of New Drugs to Augment The Growth of Market | Merck & Co., Inc, AstraZeneca PLC, NFlection Therapeutics

Market Overview:

Neurofibromatosis type-1 (NF1) is a rare disease condition characterized by changes in skin color (pigmentation) and growth of tumors in the skin nerves and other parts of the body. Signs and symptoms of this condition varies widely among those affected. In children, NF1 displays multiple patches of skin surrounded by dark pigmentation, which can enlarge and form freckles in the underarms, while in adults they develop non-cancerous tumors in the spinal cord or along the nerves in the patient’s body. There is no cure for neurofibromatosis, but signs and symptoms can be managed. Generally, the sooner someone is under the care of a doctor trained in treating neurofibromatosis, the better the outcome.

Get PDF Sample Copy of Report (Including Full TOC, List of Tables & Figures, Chart) @ https://www.coherentmarketinsights.com/insight/request-sample/4149

Competitive Landscape:

Major players operating in the global neurofibromatosis type-1 market are Healx, AstraZeneca PLC, Merck & Co., Inc, Pharm Tech Corporation, and NFlection Therapeutics, among others.

Key Market Drivers:

Increasing cases of neurofibromatosis type-1 around the world is expected to propel growth of the neurofibromatosis type-1 market during the forecast period. For instance, according to the National Cancer Institute, because NF1 is relatively rare, around 1 in 2,500 to 3,000 people are thought to be living with the condition, it is unlikely for any hospital or clinic to come across more than a handful of individuals with NF1.

Moreover, increasing demand for safe and effective treatment for NF1 is expected to augment the growth of the neurofibromatosis type-1 market. For instance, in June 2020, AstraZeneca announced that selumetinib has been granted orphan drug designation (ODD) in Japan for the treatment of neurofibromatosis type 1 (NF1). The Japanese Ministry of Health, Labour and Welfare grants ODD to medicines intended for the treatment of diseases that affect fewer than 50,000 patients in Japan and for which there is a high unmet medical need.

COVID-19 Impact Analysis:

Many people with neurofibromatosis have concerns about whether their NF diagnosis places them at high risk of side effects from the COVID-19 vaccine. However, there are no evidence of specific safety concerns related to the COVID-19 vaccine in individuals with NF. According to the Centers for Disease Control and Prevention (CDC), such medical conditions may place people at high risk of severe illness from COVID-19. Thus, it is important to minimize possible exposure and follow safety guidelines.

Key Takeaways:

• The neurofibromatosis type-1 market is expected to exhibit a CAGR of 11.3 % during the forecast period owing to the frequent approvals and launches of novel drugs in the market. For instance, in April 2020, AstraZeneca and Merck & Co. announced that the U.S. Food and Drug Administration (FDA) has approved the kinase inhibitor Koselugo (selumetinib) for the treatment of paediatric patients two years of age and older with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN).
• Among regions, North America, Europe, and Asia Pacific are expected to witness robust growth in the neurofibromatosis type-1 market owing to the increasing demand for safe and effective treatment, rise in cases of neurofibromatosis type-1, increasing focus on research and development, and frequent approvals and launches of novel drugs in these regions.

For instance, in June 2020, Nflection Therapeutics received US$ 20 million funding from Venbio Partners and F-prime Capitals. The company also announced the initiation of the first clinical trial of its lead product, NFX-179 Gel, a topically applied therapy. The Phase 2a study will be safety, tolerability, and pharmacokinetic/pharmacodynamic study of NFX-179 Gel in adult patients with cutaneous NF1.

Reasons to Buy this Neurofibromatosis Type-1 Market Report

➡ Save time carrying out entry-level research by identifying the size, growth, and leading players in the emerging Neurofibromatosis Type-1 Market

➡Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the emerging Neurofibromatosis Type-1 Market

➡Leading company profiles reveal details of key Neurofibromatosis Type-1 Market players emerging five operations and financial performance

➡Add weight to presentations and pitches by understanding the future growth prospects of the emerging Neurofibromatosis Type-1 Market with five year historical forecasts

➡Compares data from North America, South America, Asia Pacific Europe and Middle East Africa, alongside individual chapters on each region .

Direct Purchase This Report with Flat USD 2000 Off @ https://www.coherentmarketinsights.com/promo/buynow/4149

Table of Content

Chapter 1 Industry Overview
1.1 Definition
1.2 Assumptions
1.3 Research Scope
1.4 Market Analysis by Regions
1.5 Neurofibromatosis Type-1 Market Size Analysis from 2021 to 2028
11.6 COVID-19 Outbreak: Neurofibromatosis Type-1 Industry Impact

Chapter 2 Global Neurofibromatosis Type-1 Competition by Types, Applications, and Top Regions and Countries
2.1 Global Neurofibromatosis Type-1 (Volume and Value) by Type
2.3 Global Neurofibromatosis Type-1 (Volume and Value) by Regions

Chapter 3 Production Market Analysis
3.1 Global Production Market Analysis
3.2 Regional Production Market Analysis

Chapter 4 Global Neurofibromatosis Type-1 Sales, Consumption, Export, Import by Regions (2016-2021)
Chapter 5 North America Neurofibromatosis Type-1 Market Analysis
Chapter 6 East Asia Neurofibromatosis Type-1 Market Analysis
Chapter 7 Europe Neurofibromatosis Type-1 Market Analysis
Chapter 8 South Asia Neurofibromatosis Type-1 Market Analysis
Chapter 9 Southeast Asia Neurofibromatosis Type-1 Market Analysis
Chapter 10 Middle East Neurofibromatosis Type-1 Market Analysis
Chapter 11 Africa Neurofibromatosis Type-1 Market Analysis
Chapter 12 Oceania Neurofibromatosis Type-1 Market Analysis
Chapter 13 South America Neurofibromatosis Type-1 Market Analysis
Chapter 14 Company Profiles and Key Figures in Neurofibromatosis Type-1 Business
Chapter 15 Global Neurofibromatosis Type-1 Market Forecast (2021-2027)
Chapter 16 Conclusions
Research Methodology